Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology
We chose arginate over acetate because it is more stable for oral delivery, which matters when you are taking it as a capsule rather than an injection
These thin, short needles are designed for subcutaneous injection and minimize discomfort
Delivery options include creams, serums, gels and oral/sublingual adjuncts
concentration is calculated by dividing vial content (mg) by the volume of bacteriostatic water added (mL), and any figures are illustrative only
